Merck Moves To Block Generic Ganirelix Fertility Treatment

Law360, New York (August 28, 2012, 12:40 PM EDT) -- Merck & Co. Inc. and its subsidiaries lodged a patent infringement suit Monday in New Jersey federal court in an effort to block Sun Pharmaceutical Industries Ltd.'s plans to release a generic version of Merck's fertility treatment Ganirelix.

Whitehouse Station, N.J.-based Merck and subsidiaries Organon USA Inc., MSD Oss BV and Roche Palo Alto LLC allege that Sun and its affiliate Caraco Pharmaceutical Laboratories Inc. infringed two patents covering its highly successful Ganirelix Acetate Injection treatment.

“Upon information and belief, Sun’s submission of ANDA No. 20-4246...
To view the full article, register now.